Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
LifeMD
LFMD
LifeMD
Intensifying Regulation And Churn Will Limit Prospects While Stability Emerges
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
20.9% undervalued
intrinsic discount
22 Aug
US$6.33
Loading
1Y
16.1%
7D
-1.6%
Author's Valuation
US$8.0
20.9% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
20.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-75m
380m
2014
2017
2020
2023
2025
2026
2028
Revenue US$380.1m
Earnings US$15.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.57%
Healthtech revenue growth rate
4.12%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.98%
Calculation
US$15.17m
Earnings '28
x
41.32x
PE Ratio '28
=
US$626.75m
Market Cap '28
US$626.75m
Market Cap '28
/
62.22m
No. shares '28
=
US$10.07
Share Price '28
US$10.07
Share Price '28
Discounted to 2025 @ 7.98% p.a.
=
US$8.00
Fair Value '25
